Effect of Short Term Growth Hormone Releasing Hormone in Healthy Men

• Status: Completed
• Trial end date: 2010-04-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this trial is to examine the short-term effects of Growth Hormone Releasing Hormone (GHRH, tesamorelin) administration in healthy men. We hypothesize that GHRH will increase GH pulse height and will not affect insulin sensitivity.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Massachusetts General Hospital
• Collaborator: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• Treatments: Growth Hormone-Releasing Hormone; Hormones; Tesamorelin

Criteria

Inclusion Criteria:

• Men aged 18-60 years

• BMI > 20kg/m2 and <35kg/m2

Exclusion Criteria:

• Use of anti-diabetic agents, Megace, testosterone or any steroid use within 6 months of the study

• Use of GH or growth hormone stimulating peptides within six months of starting the study

• Change in lipid lowering or antihypertensive regimen within 3 months of screening

• Fasting blood sugar > 126 mg/dL, SGOT > 2.5 times ULN, Hgb < 12.0 g/dL, creatinine > 1.4 mg/dL

• Carpal tunnel syndrome

• Severe chronic illness or active malignancy or history of pituitary malignancy or history of colon cancer

• For men, history of prostate cancer or evidence of prostate malignancy by PSA > 5 ng/mL

• Prior history of hypopituitarism, head irradiation or any other condition known to affect the GH axis

• Weight < 110 lbs.